Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries in Europe
November 30, 2023 05:00 ET
|
Biocon Biologics
BENGALURU, India, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the integration of the Viatris’...
SecureKloud Hosts Exclusive CIO Roundtable on the Future of Cloud Security and Compliance
July 27, 2023 06:00 ET
|
SecureKloud Technologies Limited
NEW DELHI, India, July 27, 2023 (GLOBE NEWSWIRE) -- SecureKloud Technologies, Inc., a global leader in cloud services delivering cloud excellence with unwavering security & trust, in association...
Lupin and Exeltis Announce Reimbursement Approval of NaMuscla® in Spain for the Symptomatic Treatment of Myotonia in Adults with non-dystrophic myotonic (NDM) Disorders
January 09, 2023 07:00 ET
|
Lupin Ltd
Lupin and Exeltis Announce Reimbursement Approval of NaMuscla® in Spain for the Symptomatic Treatment of Myotonia in Adults with non-dystrophic myotonic (NDM) Disorders Agreement enables sustainable...
TVS Motor Company expands its global footprint; launches its first TVS Experience Centre in Singapore
November 24, 2022 02:45 ET
|
TVS Motor Company
SINGAPORE, Nov. 24, 2022 (GLOBE NEWSWIRE) -- TVS Motor Company, a reputed manufacturer of two-wheelers with sales of over three million units globally, today inaugurated its first state-of-the-art...
Coforge’s Copasys Automated Compliance Audit and Quality Assurance Platform Receives US Patent
September 29, 2022 11:57 ET
|
Coforge
GREATER NOIDA, India, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Coforge Limited (NSE: COFORGE), a global digital services and solutions provider, today announced it has been granted a US patent for its...
Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla®
February 09, 2022 07:23 ET
|
Lupin Ltd
Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla® Agreement enables expanded patient access of the only EU-approved treatment for myotonia symptoms in non-dystrophic myotonic...
Lupin’s Namuscla® (mexiletine) is recommended by NICE for treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM)
November 04, 2021 08:31 ET
|
Lupin Ltd
FOR UK MEDICAL AND TRADE MEDIA ONLY Lupin’s Namuscla® (mexiletine) is recommended by NICE for treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM) Slough, UK, 4...
Lupin responds to NICE Appraisal Consultation Document (ACD) on NaMuscla® (mexiletine) to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM)
February 16, 2021 02:00 ET
|
Lupin Ltd
Lupin responds to NICE Appraisal Consultation Document (ACD) on NaMuscla® (mexiletine) to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM) Slough, UK, 16th February...
Scottish Medicines Consortium approves Lupin's NaMuscla® (mexiletine) to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM)
December 08, 2020 04:00 ET
|
Lupin Ltd
Scottish Medicines Consortium approves NaMuscla® (mexiletine) to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM) Slough, UK, 8 December 2020: Lupin welcomes the...
Adani a été classé le plus important propriétaire de centrales solaires au monde
September 01, 2020 17:36 ET
|
Adani Green Energy
Son portefeuille mondial de 12,32 GWac dépasse la capacité totale installée de l'ensemble du secteur solaire aux États-Unis en 2019 SYNOPSIS Mercom Capital classe Adani Group au premier rang...